Deutsch English Français

Contact

EP1835898

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP1835898

EP1835898 - METHODS FOR MODULATING TUMOR GROWTH AND METASTASIS [Right-click to bookmark this link]
Status	The application has been withdrawn Status updated on 18.05.2012 Database last updated on 03.10.2024
Most recent event Tooltip	18.05.2012	Withdrawal of application	published on 20.06.2012 [2012/25]
Applicant(s)	For all designated states OXIGENE, INC. 230 Third Avenue Waltham, MA 02451 / US
	[2007/39]
Inventor(s)	01 / CHAPLIN, David J. 14 Plowden Park, Aston Rowant Watlington, Oxforshore OX9 5SX / GB
	02 / EDVARDSEN, Klaus Genmab, Toldbodgade 55B 1253 Copenhagen K / DK
	03 / YOUNG, Scott 105 Old Bolton Road Stowe, Massachusetts 01775 / US
	[2008/23]
Former [2008/02]	01 / CHAPLIN, David J. 14 Plowden Park, Aston Rowant Watlington, Oxforshore OX9 5SX / GB
	02 / EDVARDSEN, Klaus Klampenborgvei 16 DK - 2930 Klampenborg / DK
	03 / YOUNG, Scott 105 Old Bolton Road Stowe, Massachusetts 01775 / US
Former [2007/39]	01 / CHAPLIN, David J. 14 Plowden Park, Aston Rowant Watlington, Oxforshore OX9 5SX / GB
	02 / EDVARDSEN, Klaus Stora Grabrodersgatan 13 S-222 22 Lund / SE
	03 / YOUNG, Scott 105 Old Bolton Road Stowe, Massachusetts 01775 / US
Representative(s)	Crump, Julian Richard John, et al Mintz Levin Cohn Ferris Glovsky & Popeo Intellectual Property LLP Alder Castle 10 Noble Street London EC2V 7JX / GB
	[N/P]
Former [2007/39]	Crump, Julian Richard John, et al Mintz Levin Cohn Ferris Glovsky & Popeo Intellectual Property LLP The Rectory 9 Ironmonger Lane London EC2V 8EY / GB
Application number, filing date	05857206.6	22.12.2005
	[2007/39]
	WO2005US46960
Priority number, date	US20040020463	22.12.2004 Original published format: US 20463
	[2007/39]
Filing language	EN
Procedural language	EN
Publication	Type:	A2 Application without search report
	No.:	WO2006078422
	Date:	27.07.2006
	Language:	EN
	[2006/30]
	Type:	A2 Application without search report
	No.:	EP1835898
	Date:	26.09.2007
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 27.07.2006 takes the place of the publication of the European patent application.
	[2007/39]
Search report(s)	International search report - published on:	EP	08.02.2007
Classification	IPC:	A61K31/09, A61P35/00, A61K31/337, A61K31/555, G01N33/50	[2007/39]
	CPC:	A61K31/09 (EP,US); A61K31/05 (EP,US); A61K31/337 (EP,US); A61K31/555 (EP,US); A61K33/243 (EP,US); A61K45/06 (EP,US); (+) A61P35/00 (EP); A61P35/04 (EP); A61P43/00 (EP); A61P9/00 (EP) (-)
	C-Set:	A61K31/05, A61K2300/00 (EP,US)
Designated contracting states	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR [2007/39]
Extension states	AL	Not yet paid
	BA	Not yet paid
	HR	Not yet paid
	MK	Not yet paid
	YU	Not yet paid
Title	German:	VERFAHREN ZUR MODULATION DES TUMORWACHSTUMS UND VON METASTASEN	[2007/39]
	English:	METHODS FOR MODULATING TUMOR GROWTH AND METASTASIS	[2007/39]
	French:	METHODE DE MODULATION DE LA CROISSANCE TUMORALE ET DES METASTASES	[2007/39]
Entry into regional phase	23.07.2007	National basic fee paid
	23.07.2007	Designation fee(s) paid
	23.07.2007	Examination fee paid
Examination procedure	23.07.2007	Amendment by applicant (claims and/or description)
	23.07.2007	Examination requested [2007/39]
	19.02.2009	Despatch of a communication from the examining division (Time limit: M06)
	28.08.2009	Reply to a communication from the examining division
	29.03.2010	Despatch of a communication from the examining division (Time limit: M06)
	12.11.2010	Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
	12.01.2011	Reply to a communication from the examining division
	15.05.2012	Application withdrawn by applicant [2012/25]
	16.05.2012	Cancellation of oral proceeding that was planned for 18.07.2012
	18.07.2012	Date of oral proceedings (cancelled)
Divisional application(s)	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 19.02.2009
Request for further processing for:	The application is deemed to be withdrawn due to failure to reply to the examination report
	13.01.2011	Request for further processing filed
	13.01.2011	Full payment received (date of receipt of payment) Request granted
	27.01.2011	Decision despatched
Fees paid	Renewal fee
	23.07.2007	Renewal fee patent year 03
	24.12.2008	Renewal fee patent year 04
	28.12.2009	Renewal fee patent year 05
	27.12.2010	Renewal fee patent year 06
	27.12.2011	Renewal fee patent year 07
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited in	International search	[X]EP1068870 (AJINOMOTO KK [JP]) [X] 15,16,20-22,25,27,32 * claims 3,4 *;
		[X]WO02056692 (BRISTOL MYERS SQUIBB CO [US], et al) [X] 15-22,25-27,32 * claims 1,4 *;
		[X]WO02074229 (AVENTIS PHARMA SA [FR]) [X] 15-17,20,25,27,32 * claims 2-8,17 *;
		[X] - ANONYMOUS, INTERNET ARTICLE, URL: http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=OXGN&script=416&layout=0&item_id=655483, (20041216), XP002386512 [X] 1-4,6,7,9-11,13,15-18,20,21,23-25,27,33-37,39-41,44-48,51 * the whole document *
		[X] - "745 poster Tumour antivascular effects of combretastatin a-4 phosphate (CA4P) in combination with radiotherapy measured using dynamic contrast enhanced computed tomography (DCE-CT)", RADIOTHERAPY AND ONCOLOGY, ELSEVIER, (200410), vol. 73, ISSN 0167-8140, page S322, XP005069193 [X] 15,16,25-27,32 * abstract *
		[X] - NELKIN B D ET AL, "COMBRETASTATIN A-4 AND DOXORUBICIN COMBINATION TREATMENT IF EFFECTIVE IN A PRECLINICAL MODEL OF HUMAN MEDULLARY THYROID CARCINOMA", ONCOLOGY REPORTS, NATIONAL HELLENIC RESEARCH FOUNDATION, ATHENS, GR, (200101), vol. 8, no. 1, ISSN 1021-335X, pages 157 - 160, XP008013083 [X] 15,16,25-27 * the whole document *
		[X] - GROSIOS K ET AL, "COMBINATION CHEMOTHERAPY WITH COMBRETASTATIN A-4 PHOSPHATE AND 5-FLUOROURACIL IN AN EXPERIMENTAL MURINE COLON ADENOCARCINOMA", ANTICANCER RESEARCH, HELENIC ANTICANCER INSTITUTE, ATHENS,, GR, (200001), vol. 20, no. 1A, ISSN 0250-7005, pages 229 - 233, XP008012523 [X] 15,16,25,27 * the whole document *
		[A] - YOUNG SCOTT L; CHAPLIN DAVID J, "Combretastatin A4 phosphate: background and current clinical status", EXPERT OPINION ON INVESTIGATIONAL DRUGS, (200409), vol. 13, no. 9, pages 1171 - 1182, XP002386513 [A] * page 1175; table 1 *
		[A] - SIEMANN DIETMAR W; CHAPLIN DAVID J; HORSMAN MICHAEL R, "Vascular-targeting therapies for treatment of malignant disease", CANCER, (20040612), vol. 100, no. 12, pages 2491 - 2499, XP002386514 [A] * page 2496; table 2 * DOI: http://dx.doi.org/10.1002/cncr.20299
	Examination	- YAMAMOTO KENJI ET AL, "Modulation of cisplatin sensitivity by taxol in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines", JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, (200003), vol. 126, no. 3, ISSN 0171-5216, pages 168 - 172
		- KOMURO YUUKI ET AL, "Paclitaxel and SN-38 overcome cisplatin resistance of ovarian cancer cell lines by down-regulating the influx and efflux system of cisplatin", JAPANESE JOURNAL OF CANCER RESEARCH, (200111), vol. 92, no. 11, ISSN 0910-5050, pages 1242 - 1250

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 35p